Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ADAMTS13 encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) protein family. Additionally we are shipping ADAMTS13 Kits (28) and ADAMTS13 Proteins (6) and many more products for this protein.
Showing 10 out of 86 products:
Human Polyclonal ADAMTS13 Primary Antibody for EIA, IHC (p) - ABIN359601
Levy, Nichols, Lian, Foroud, McClintick, McGee, Yang, Siemieniak, Stark, Gruppo, Sarode, Shurin, Chandrasekaran, Stabler, Sabio, Bouhassira, Upshaw, Ginsburg, Tsai: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. in Nature 2001
Show all 7 references for ABIN359601
Human Polyclonal ADAMTS13 Primary Antibody for WB - ABIN152016
Tao, Wang, Choi, Bernardo, Nishio, Sadler, López, Dong: Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. in Blood 2005
Show all 5 references for ABIN152016
Human Polyclonal ADAMTS13 Primary Antibody for ELISA, IHC - ABIN4278265
Ganburged, Suda, Saito, Yamazaki, Isokawa, Moriyama: Dilated capillaries, disorganized collagen fibers and differential gene expression in periodontal ligaments of hypomorphic fibrillin-1 mice. in Cell and tissue research 2010
Show all 3 references for ABIN4278265
Human Polyclonal ADAMTS13 Primary Antibody for IHC (p), WB - ABIN391641
Zheng, Chung, Takayama, Majerus, Sadler, Fujikawa: Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. in The Journal of biological chemistry 2001
Show all 3 references for ABIN391641
Human Polyclonal ADAMTS13 Primary Antibody for IP, WB - ABIN251718
Feng, Eyler, Zhang, Maga, Nester, Kroll, Smith, Afshar-Kharghan: Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. in Blood 2013
Show all 2 references for ABIN251718
Human Polyclonal ADAMTS13 Primary Antibody for WB - ABIN251717
Turner, Nolasco, Ruggeri, Moake: Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. in Blood 2009
administration of ADAMTS13 5 minutes after occlusion dose-dependently dissolved these t-PA (show PLAT Antibodies)-resistant thrombi resulting in fast restoration of MCA (show RSPH1 Antibodies) patency and consequently reduced cerebral infarct sizes
Sleeping beauty transposon-mediated gene therapy achieved sustained expression of transgene ADAMTS13 and long-term prophylaxis against congenital thrombotic thrombocytopenic purpura in Adamts13(-/-) mice.
Results also suggest that Toxoplasma gondii-mediated apoptosis might play a pivotal role and a different type of role in the mechanism of neurodegeneration and neuropathology in the process of toxoplasma encephalitis. Furthermore, expression of ADAMTS-13 might give an idea of the progress and is critical for diagnosis of this disease.
Letter: deficiency of ADAMTS13 results in increased formation of venous thrombosis in mice.
ADAMTS13 substrate specificity
Data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and may contribute to thrombotic thrombocytopenic purpura.
Data show that metalloendopeptidase (show THOP1 Antibodies) ADAMTS13 does not directly promote development of adipose tissue.
findings provide further evidence on the pathophysiological role for the ADAMTS13/VWF (show VWF Antibodies) axis in atherosclerosis
Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor (show VWF Antibodies) string formation under flow in a free-thiol-dependent manner.
The results indicate that the microvascular process induced by ADAMTS13 deficiency triggers complement activation on platelets and the endothelium, which may contribute to formation of thrombotic microangiopathy.
ADAMTS13 activity and VWF:Ag levels are both associated with an increased risk of all-cause and cardiovascular mortality.
These findings support an ADAMTS13 activation model in which VWF (show VWF Antibodies) D4-CK engages the TSP8-CUB2 domains, inducing the conformational change that disrupts the CUB1-spacer domain interaction and thereby activates ADAMTS13
Three cases of systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy were successfully treated with combination of mycophenolate mofetil, plasma exchange and steroid. [case reports]
The pregnancy loss rate does not appear to be affected by both ADAMTS-13 and ADAMTS-19.
Two novel ADAMTS13 mutations (p.I143T and p.Y570C) identified in two adolescence onset congenital thrombotic thrombocytopenic purpura patients were studied. Proteasome degradation of these ADAMTS13 mutants contributed to their reduced secretion.
Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients.
review to introduce the state of progress with respect to some of the theorized roles of ADAMTS13[review]
IL-8 (show IL8 Antibodies), TNF-alpha (show TNF Antibodies), tissue factor (show F3 Antibodies), IL-8 (show IL8 Antibodies)+tissue factor (show F3 Antibodies) and TNF-alpha (show TNF Antibodies)+tissue factor (show F3 Antibodies) decreased the levels of ADAMTS13 secreted by umbilical vein endothelial cells.
Significantly lower ADAMTS-13 levels and significantly higher VWF (show VWF Antibodies) antigen levels were concluded to be the result of a pathological process rather than an etiological factor for Venous thromboembolism.
ADAMTS13 and VWF (show VWF Antibodies) are co-expressed in microvascular endothelial cells.
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The enzyme encoded by this gene is the von Willebrand Factor (vWF)-cleaving protease, which is responsible for cleaving at the site of Tyr842-Met843 of the vWF molecule. A deficiency of this enzyme is associated with thrombotic thrombocytopenic purpura. Alternative splicing of this gene generates multiple transcript variants encoding different isoforms.
ADAM metallopeptidase with thrombospondin type 1 motif, 13
, ADAM metallopeptidase with thrombospondin type 1 motif, 13 isoform 1 preproprotein-like
, A disintegrin and metalloproteinase with thrombospondin motifs 13-like
, ADAM metallopeptidase with thrombospondin type 1 motif, 12
, A disintegrin and metalloproteinase with thrombospondin motifs 12
, A disintegrin and metalloproteinase with thrombospondin motifs 13
, ADAM-TS 13
, ADAMTS13 isoform IAP-b
, a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 13
, vWF-CP mRNA for von Willebrand factor-cleaving
, vWF-cleaving protease
, von Willebrand factor-cleaving protease
, a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13